First European experience with human MTP-inhibitor in HoFH
Dr. Jeanine Roeters van Lennep10' education - Oct. 24, 2014
Jeanine Roeters van Lennep, MD PhD (Erasmus MC, Rotterdam, The Netherlands) discusses management of homozygous familial hypercholesterolaemia (HoFH). Recently a position paper was published that discussed causes, diagnosis and treatment options of this difficult to treat condition. Dr. Roeters van Lennep focuses on treatment with the first human MTP-inhibitor, lomitapide. Although it is not reimbursed yet in The Netherlands, the Erasmus Medical Center in Rotterdam has started treating the first patients with lomitapide on a named-patient basis. Roeters van Lennep shares the first experiences in these patients.
After having watched this 10’ education you will know more about:
- the mechanism of action of an MTP-inhibitor
- how patients should be educated, guided and tested prior to treatment with lomitapide
- how the first patients with HoFH (various age categories, genotypes and sexes) respond to treatment with lomitapide.